Phase Iii Study Of The Hypoxia-Inducible Factor 2 Alpha (Hif-2 Alpha) Inhibitor Mk-6482 Versus Everolimus In Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma (Ccrcc).

Toni K. Choueiri,Laurence Albiges,Li Fan,Rodolfo F. Perini,Naseem J. Zojwalla,Thomas Powles,Brian I. Rini

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 10|浏览2

暂无评分

摘要

TPS5094Background: In RCC, the Von Hippel-Lindau (VHL) tumor suppressor gene is inactivated in most cases, resulting in the accumulation and overactivation of HIF-2α. HIF-2α is a key oncogenic driv...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要